Why the study?
Performance in the Wingate Anaerobic Test is influenced by many variables including genetics, but the specific genes related to performance required systematic analysis.
Do specific genetic variants influence performance on the Wingate Anaerobic Test?
Do specific genetic variants influence performance on the Wingate Anaerobic Test?
Genetic variants such as PPARA and UCP2 may positively influence anaerobic performance on the Wingate Anaerobic Test, while evidence for ACTN3 and AMPD remains contradictory.
Answers are grounded in this paper and cite their sources.
Genetic screening offers limited guidance for WAnT assessment; larger studies needed to validate PPARA/UCP2 associations.
Anaerobic performance is decisive in many sports. The Wingate Anaerobic Test (WAnT) is the most widely used test for the assessment of anaerobic performance to date. Performance in this test is influenced by many variables, including genetics. The aim of this review is to analyze the genes related to WAnT performance. A detailed search of four databases (Pubmed, Scopus, Web of Science and Cochrane Library) was conducted until February 2022. This literature search was implemented according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Nine eligible studies were selected from the 153 records identified. 3 articles for the ACTN3 gene, 2 for AMPD, one combined ACTN3 and AMPD, 1 article each for PPARA, UCP2 and MCT1. The genes ACTN3 and AMPD seem to report contradictory literature regarding its influence on WAnT peak power (PP), mean power and fatigue index. The MCT1 gene seems to have no influence, and the PPARA and UCP2 genes seem to have a positive relationship with PP.
No takes yet. Share an insight, caveat, or question.
Castañeda-Babarro et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: